by Madaline Spencer | Jan 5, 2026
Binod Dhakal, MD, Associate Professor of Medicine at Medical College of Wisconsin, discusses results from the CARTITUDE-4 clinical trial in patients with multiple myeloma (MM). MM is a form of cancer that occurs due to abnormal and uncontrolled growth of...
by Madaline Spencer | Jan 2, 2026
Jean-Marie Michot, MD, Institut Gustave Roussy, France, discusses results from Part 1A (dose escalation) of the OLYMPIA-3 study of odronextamab plus chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is a form of non-Hodgkin...
by Madaline Spencer | Dec 30, 2025
Paolo Ghia, MD, PhD, Professor of Medical Oncology at the Università Vita-Salute San Raffaele in Milan, Italy, discusses data comparing ibrutinib plus venetoclax combination therapy with chlorambucil + obinutuzumab combination therapy in patients with chronic...
by Madaline Spencer | Dec 29, 2025
Robert Orlowski, MD, PhD, Professor of Medicine at the University of Texas MD Anderson Cancer Center, discusses results from the LINKER-MM4 clinical trial testing Lynozyfic (linvoseltamab) to treat patients with newly diagnosed multiple myeloma (MM). MM is a...
by Madaline Spencer | Dec 23, 2025
Elias Jabbour, MD, MD Anderson Cancer Center at the University of Texas, discusses the cAMeLot-2 study design of bleximenib combination therapy for patients with acute myeloid leukemia (AML). AML is a hematologic malignancy. Early signs and symptoms of...
